title: Benefit of cyclophosphamide therapy in IgA nephritis may have been obscured by warfarin-related nephropathy in the randomized trials in which warfarin and dipyridamole were used in combination with cyclophosphamide.
authors.forename: Sergey V
authors.initials: SV
authors.lastname: Brodsky
authors.forename: Brad H
authors.initials: BH
authors.lastname: Rovin
authors.forename: Lee A
authors.initials: LA
authors.lastname: Hebert
mesh_terms: D058186:Acute Kidney Injury / Q000139:chemically induced* / Q000473:pathology; D000328:Adult; D002648:Child; D015331:Cohort Studies; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use*; D004176:Dipyridamole / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D005922:Glomerulonephritis, IGA / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008297:Male; D016032:Randomized Controlled Trials as Topic; D012189:Retrospective Studies; D018570:Risk Assessment; D016896:Treatment Outcome; D014859:Warfarin / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D014859:Warfarin; D004176:Dipyridamole; D003520:Cyclophosphamide